Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/bacterial-chassis-promoter-engineering-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Bacterial Chassis Promoter EngineeringBacterial Chassis Promoter Engineering Patents: Who Leads and Where the Field Is Still Open
- 26.5% concentration at the top. The five leading assignees together hold 1,416 of the 5,348 records in scope, but the sixth-ranked filer onward drops off fast into a long tail.
- Filings down 61% from 2021 to 2024. Complete-year filings fell from 206 in 2021 to 80 in 2024, a real slowdown, not an artefact of publication lag.
- C12N dominates, but half the field also touches C12Q. 84.4% of records sit in microorganism/genetic-engineering classes, while measuring-and-testing claims (C12Q) run through exactly half the corpus.
5,348
Published Records
26%
Top-5 Share of All Records
-61%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (206 records) with 2024 (80) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 5,348 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Bacterial chassis promoter engineering sits at the intersection of synthetic biology and industrial microbiology: constructs that tune transcription strength in a host bacterium through inducible or constitutive promoter design, operator sequence variation, and reporter-assay validation. The scope here is defined by search terms spanning engineered or recombinant bacterial hosts combined with promoter-mutation, operator-sequence, transcription-strength, inducible/constitutive-promoter and reporter-assay language, filtered to the core genetic-engineering, microorganism-culture and DNA/enzyme-measurement classification codes (C12N15/09, C12N1/20, C12Q1/68).
5,348 records fall inside this scope, spanning filings from 2015 through the 2026 data cut-off. Because publication typically lags filing by around 18 months, the most recent one to two years in any trend understate real filing activity and should be read as provisional.
Filing activity and technology mix, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The data
Filing trend and technology composition
Two views of the same 5,348-record corpus: how filing activity has moved year over year, and which classification codes carry the claim density.
Filings peaked in 2017 and have since declined
Annual filings peaked at 248 in 2017. Complete-year data shows a drop from 206 filings in 2021 to 80 in 2024, a 61% decline over that three-year span. 2025 and 2026 figures are still filling in under normal publication lag and should not be read as a continuation of the decline until later data confirms it.
C12N and the split between production and measurement claims
C12N (microorganisms and genetic engineering) touches 84.4% of the 5,348 records, confirming this is fundamentally a host-engineering field. C07K (peptides/proteins) and C12Q (enzyme/DNA measurement) each sit at exactly 50.0%, while C12P (fermentation and enzymatic synthesis) reaches 38.6% — together indicating that most filings pair a promoter or host-engineering claim with either a production step or a testing/reporter-assay step, rather than claiming the promoter mechanism in isolation.
Shares are the percentage of the 5,348 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Bacterial Chassis Promoter Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about bacterial chassis promoter engineering and every answer comes back with the patent numbers behind it.
Try EurekaKey patents
A representative recent filing and the most-cited prior art
Representative recent filing
WO2026082878A1 — Auto-inducible promoter engineering
LONZA LTD
A bacterial expression construct pairs an auto-inducible promoter with a Shine-Dalgarno sequence heterologous to that promoter, so that carbon-depletion triggers expression and the SD sequence tunes promoter strength independently of the induction signal. The claim covers both the expression construct and the auto-inducible promoter element itself, plus expression systems built on it.Filed by Lonza, published 2026-04-23 — illustrates the current move toward decoupling induction signal from expression strength via SD-sequence tuning rather than promoter-sequence mutation alone.
Most-cited records in this corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5223409A | Directed evolution of novel binding proteins | 14,049 |
| 2 | US5789199A | Process for bacterial production of polypeptides | 2,622 |
| 3 | US5516637A | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage | 2,218 |
| 4 | WO1994012649A2 | Gene therapy for cystic fibrosis | 2,130 |
| 5 | WO1992000377A1 | Glyphosate tolerant plants | 1,837 |
| 6 | US5776760A | Glyphosate tolerant plants | 1,153 |
| 7 | WO1995019431A1 | Zinc finger protein derivatives and methods therefor | 1,119 |
| 8 | WO1998054311A1 | Zinc finger protein derivatives and methods therefor | 1,077 |
| 9 | US6140466A | Zinc finger protein derivatives and methods therefor | 1,029 |
| 10 | US20050042664A1 | Humanization of antibodies | 1,022 |
Citation counts favour older filings simply because they have had more time to accumulate citations within the searched corpus — treat them as a signal of influence on the field, not as a marker of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing or freedom-to-operate decision
Three findings that change how a search or a claim strategy in this space should be scoped.
Concentration
26.5%
of 5,348 records held by the top 5 assignees
The top of the field is concentrated, the rest is fragmented
The top 5 assignees combined account for 26.5% of all 5,348 records in scope, and the top 10 for 36.2%. Beyond that the ranking thins quickly — fifth place sits at 159 records and tenth at 92 — meaning most of the corpus is held by single-digit filers rather than a handful of dominant players.
Freedom-to-operate work should still check the long tail, not just the leaders.
Momentum
-61%
filings 2021 → 2024 (complete years)
A real decline in complete-year filings, not a lag artefact
Filings dropped from 206 in 2021 to 80 in 2024 — a genuine three-year decline that predates the publication-lag window. Several of the leading assignees show flat or negative year-on-year momentum in the most recent complete year, consistent with a maturing rather than expanding filing wave.
New entrants may be filing into a field where the leaders have already slowed.
Composition
50.0%
of records also classified under C12Q
Promoter claims rarely stand alone
Exactly half of the 5,348 records also carry a C12Q measuring/testing classification, and half carry C07K peptide/protein claims. This says claim drafting in this field routinely bundles the promoter or operator element with a downstream assay or expressed-product claim rather than filing the regulatory element by itself.
A standalone promoter-only claim is the exception, not the norm, in this corpus.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bacterial chassis promoter engineering, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the collaboration lies
The ranking covers 100 assignees returned by the data endpoint — not a curated top-50 or top-100 list, just the full ranking as the dataset returns it. A small number of academic and life-sciences filers dominate the citation network, but co-filing between them is limited to a handful of strong pairs.
Leader
620
records
One filer well ahead of the rest
The leading assignee holds 620 records, more than three times the fifth-place filer's 159. That gap suggests a sustained, multi-year filing programme rather than opportunistic filing around a single product.
Worth a dedicated prior-art review before filing into adjacent claim space.
Collaboration
10
co-assignee pairs identified
Academic co-filing clusters around a few named inventors
The strongest co-assignee pairs link two university systems together, and separately link each university to a named academic inventor, with pair strengths in the 102–108 record range. This points to CRISPR-adjacent academic programmes rather than industrial joint ventures as the source of most co-filing in this space.
Licensing conversations in this field often run through the university offices, not the named inventor directly.
Momentum
-86% to -100%
YoY change among several leading filers
Leading filers are pulling back, not accelerating
Recent-year momentum among the most active historical filers is negative across the board, from -50% to -100% year-on-year, with several dropping to zero filings in the latest year. That is consistent with the broader 2021-2024 decline rather than a sign any single leader is retreating from the field alone.
A slowdown at the top can be an opening for a well-scoped new filing.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Oxford Nanopore Technologies Ltd | 2 | -86% |
| The Regents of the University of California | 1 | -50% |
| Novozymes A/S | 0 | -100% |
| Monsanto Technology LLC | 0 | -100% |
| Yale University | 0 | — |
| The Scripps Research Institute | 0 | — |
| University of Vienna | 0 | -100% |
| CHARPENTIER EMMANUELLE | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next
Where to take this research
The trends above point to specific next steps depending on whether the goal is freedom-to-operate, licensing, or new claim drafting.
Map the white space before drafting
The gate chips above name sub-areas with comparatively thin filing density relative to the core promoter mechanism claims. Run a focused prior-art check on carbon-depletion induction and SD-sequence tuning specifically before assuming the space is occupied.
Explore white space in EurekaTrack the leading filer's recent activity
A single assignee holds more than a third of the top-10 concentration on its own. Understanding its recent filing pattern, not just its historical volume, matters more than the raw count.
Monitor assignee activity in EurekaReassess after the 2025-2026 data settles
Because publication lag understates the most recent 18 months, re-run this landscape once 2025 filings are more fully published before concluding the decline has bottomed out.
Set a landscape refresh in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
There are 5,348 published patent records in this scope, covering filings from 2015 through the 2026 data cut-off. The search combines terms for engineered or recombinant bacterial hosts with promoter-mutation, operator-sequence, transcription-strength and reporter-assay language, restricted to the core genetic-engineering and DNA/enzyme measurement classification codes. This figure counts records, and patent families are the fairer unit for cross-jurisdiction comparison since they neutralise duplicate filings of the same invention in different countries.
The ranked leaders comprise 100 assignees identified in this dataset, with the top filer holding 620 records and a clear step down to the fifth-ranked filer at 159. The top 5 assignees combined account for 26.5% of all 5,348 records in scope, and the top 10 for 36.2%, so while there is a recognisable leading group, the majority of the field is held by a long tail of smaller filers. Several of the most active historical filers show negative year-on-year filing momentum in the latest complete year, which matters more for competitive tracking than the raw historical count.
Filings are slowing on the complete-year data available: 2021 filings stood at 206 and fell to 80 by 2024, a 61% decline over that three-year span. The peak year in the dataset was 2017 at 248 filings. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures are still filling in and should not yet be read as confirmation the decline has continued or bottomed out.
C12N, covering microorganisms and genetic engineering, touches 84.4% of the 5,348 records and is the dominant classification. C07K peptide/protein claims and C12Q enzyme/DNA measurement claims each appear in exactly 50.0% of records, and C12P fermentation/enzymatic synthesis claims appear in 38.6%. In practice this means most filings bundle the promoter or host-engineering element with either a downstream production step or a measurement/reporter-assay step, rather than claiming the regulatory element in complete isolation.
Based on the classification mix and the specific claim language emerging in recent filings such as WO2026082878A1, comparatively under-claimed branches include carbon-depletion-triggered auto-induction, Shine-Dalgarno sequence tuning as a distinct lever from promoter-sequence mutation, and cross-host promoter portability testing. These sit adjacent to the dominant C12N/C12Q claim clusters but are not yet as densely filed. A first claim in these branches would typically need to specify the induction trigger mechanism and the sequence element used to modulate strength, since broad promoter-strength claims alone are likely to run into prior art from the leading assignees.
Answers are grounded in the same dataset. Derived from a Patsnap search on Bacterial Chassis Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Bacterial Chassis Promoter Engineering in depth with Eureka
Go past this page: query the whole bacterial chassis promoter engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.